Community, connection, creativity and innovation were the big themes at Switchback‘s spring edition, which was held last week in New Orleans. The second annual standalone show, which grew out of The ...
Grail is a leader in the potentially enormous multi-cancer early detection (MCED) test market. The company could have a major catalyst on the way with the potential FDA approval of its Galleri test.
One problem for Grail is that some lump it into the same category as other genomics stocks that focus on prenatal screening. This group has become increasingly crowded. However, Grail is different -- ...
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results